Navigation Links
Ovarian Tumors May Develop Years After Fertility Therapy
Date:10/27/2011

THURSDAY, Oct. 27 (HealthDay News) -- Women who undergo ovarian stimulation to produce extra eggs for in-vitro fertilization (IVF) are at increased risk for a type of growth known as "borderline ovarian tumors," new research suggests.

Borderline ovarian tumors are typically not aggressive, according to the U.S. National Cancer Institute. Even if the tumor does spread, the vast majority of women survive borderline ovarian tumors.

Even so, treating borderline ovarian tumors can require extensive surgery, explained lead researcher Flora van Leeuwen, head of the epidemiology department in The Netherlands Cancer Institute.

For the study, researchers examined data from over 19,000 infertile women in the Netherlands who underwent ovarian stimulation prior to IVF and about 6,000 infertile women who did not undergo IVF.

After 15 years of follow-up, the women who underwent ovarian stimulation were four times more likely to develop a borderline ovarian tumor, according to the findings published in the Oct. 27 online edition of the journal Human Reproduction.

"Our data clearly show that ovarian stimulation for IVF is associated with an increased risk of borderline ovarian tumors and this risk remains elevated up to more than 15 years after the first cycle of treatment," van Leeuwen explained in a journal news release.

Overall, however, the number of women developing any sort of ovarian tumor was low. The cumulative risk in the general population of an ovarian malignancy for women under age 55 in the Netherlands is 0.45 percent. For women who undergo IVF, it's 0.71 percent, "with the increase being due to borderline tumors of the ovary," van Leeuwen added.

The low number of women in the study who developed ovarian malignancies prevented the researchers from determining if repeated IVF cycles increased the risk of ovarian malignancies. They noted in the news release that they are expanding their study population to examine that issue.

"If we find out that women who receive several IVF cycles or large doses of ovarian-stimulating drugs are at a greater risk of ovarian cancer, then these women would need to be informed about these risks when continuing IVF treatment and possibly advised to discontinue treatment after three to six cycles (depending on which number of cycles would be associated with the high risk of ovarian malignancies)," van Leeuwen noted.

The International Federation of Fertility Societies (IFFS) issued a statement in response to the new study findings. In it, general secretary of the IFFS, Richard Kennedy of Coventry, England, said: "Over the last decade, several reports have considered the long-term risks of ovarian stimulation practiced as part of the IVF process. These reports have been generally reassuring in terms of risk of ovarian cancer."

However, Kennedy added, "This new research has highlighted the presence of an increased risk of borderline tumors . . . and has once again posed a question about the long-term risks of ovarian stimulation further confounded by the known underlying risks for these patients. The IFFS remains of the view that the long-term risks are low but calls for continued vigilance through reporting of long-term outcomes with international collaboration."

More information

The American Cancer Society has more about ovarian cancer.

-- Robert Preidt

SOURCES: Human Reproduction, news release, Oct. 26, 2011; International Federation of Fertility Societies, statement, Oct. 26, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Linking of mutations in 12 genes to ovarian cancer may lead to more effective prevention
2. Terry Fox Research Institute aims to change diagnosis and management of ovarian cancer worldwide
3. Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival
4. Early detection is key in the fight against ovarian cancer
5. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
6. New hybrid imaging device shows promise in spotting hard-to-detect ovarian cancer
7. FDA clears biomarker test for ovarian cancer
8. Key function of mutation in hereditary breast and ovarian cancer gene discovered
9. Plants could pave the way for new ovarian cancer treatments
10. Trial Drug Shows Preliminary Promise Against Ovarian Cancer
11. Blood Antibody May Signal Start of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ovarian Tumors May Develop Years After Fertility Therapy
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: